Press Releases

LenioBio, the leader in rapid cell-free protein expression technologies, is pleased to announce a collaboration with ReciBioPharm, a global contract development and manufacturing organization (CDMO), to scale up protein manufacturing capabilities and expedite vaccine production. This collaboration is part of the expansion in scope of LenioBio's CEPI-funded project, which aims to showcase the capacity and speed of LenioBio's proprietary ALiCE® protein expression technolog

Calyx and Invicro businesses officially launched under its new corporate identity, Perceptive. The new name reflects the organization’s increased strengths and capabilities, as they consolidate their place as a global leader in the provision of discovery, imaging, and eClinical solutions and services. Expanding on their combined 50 + -year history, Perceptive provides best-in-class specialist support to global pharmaceutical, biotech, and clinical research organizations, spann

Moderna, Inc. today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403. Global recruitment for the Nova 301 trial has also begun. "Norovirus is a significant public health concern that affects millions of people worldwide each year, leading to severe symptoms and, in some cases, hospitalizatio

Piramal Pharma Solutions a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has unveiled an $80M investment plan to expand its Lexington, Kentucky facility. The site specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products, playing a vital role in Piramal Pharma Solutions integrated antibody-drug conjugate development and manufacturing program, ADCel

AbbVie today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. Approximately 85% of lung cancers are classified as NSCLC1 and despite advances in treatment, lun

Johnson & Johnson announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) o

Crinetics Pharmaceuticals, Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist in development for the proposed treatment and long-term maintenance therapy of acromegaly. “This NDA submission brings us one step closer to our goal of delivering a new generation of therapy that can help people living

Evaxion Biotech A/S a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it has entered into an option and license agreement with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) for two preclinical vaccine candidates. The agreement expands the companies’ current collaboration and carries significant value for Evaxion. Under the terms of the agreement, Evaxion has granted MSD an option to exclusively l

The 15th edition of MEDICAL FAIR ASIA and the 6th edition of MEDICAL MANUFACTURING ASIA, the region’s leading specialist trade fairs for the medical, healthcare, and medical technology (MedTech) sectors, concluded just under two weeks ago, achieving record attendance from both visitors and exhibitors. MEDICAL FAIR ASIA and MEDICAL MANUFACTURING ASIA 2024 welcomed an impressive turnout of 13,725 attendees, marking one of the highest attendances since its first edition in 1997,

DURECT Corporation a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today provided details on the design of its upcoming registrational Phase 3 trial which will evaluate larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH). “We are pleased with the collaborative interactions with the U.S. Food and Drug A